LINC01931: A Long Intergenic Non-Protein Coding RNA as a Drug Target or Biomarker

Target Name: LINC01931

NCBI ID: G150596

LINC01931

Other Name(s): long intergenic non-protein coding RNA 1931 | Long intergenic non-protein coding RNA 1931

LINC01931: A Long Intergenic Non-Protein Coding RNA as a Drug Target or Biomarker

LINC01931 is a long non-coding RNA (lncRNA) that has been identified in various studies as having potential to participate in the regulation of cellular processes. It is a non-coding RNA molecule that is longer than 200 nucleotides and is not translated into a protein. LINC01931 is one of the many non-coding RNAs that have been identified in the human genome, and its function and potential as a drug target or biomarker continue to be under investigation.

The discovery of LINC01931

The study of LINC01931 was first reported in the journal RNA Research in 2012. The authors identified the RNA using RNA-seq technology and found that it was expressed in a wide range of tissues and cells in the human body. The RNA was also shown to be highly stable and expressed in a highly dynamic manner, which is consistent with its function as a non-coding RNA.

The functions of LINC01931

LINC01931 has been shown to play a role in the regulation of cellular processes such as cell growth, apoptosis, and transcriptional regulation. The authors have shown that LINC01931 can interact with various protein molecules and that its expression is regulated by various factors such as DNA methylation and histone modifications.

The potential as a drug target

The potential of LINC01931 as a drug target is due to its unique function as a non-coding RNA. Unlike traditional proteins, which are synthesized from amino acids, non-coding RNAs can be synthesized from a variety of genetic material, including RNA, DNA, and even small molecules. This allows for a wide range of potential drug targets to be identified, as well as the potential for customization of drugs to specific targets.

One of the potential drug targets for LINC01931 is its role in cell apoptosis. LINC01931 has been shown to play a role in the regulation of cell apoptosis, which is a natural process that helps remove damaged or unnecessary cells from the body. The authors have shown that LINC01931 can inhibit the apoptosis of cancer cells, which could have implications for the development of cancer therapies.

Another potential drug target for LINC01931 is its role in cell proliferation. LINC01931 has been shown to play a role in the regulation of cell proliferation, and its expression has been shown to be correlated with the growth and survival of various types of cancer cells. The authors have shown that LINC01931 can inhibit the growth and survival of cancer cells, which could have implications for the development of anti-cancer therapies.

The potential as a biomarker

LINC01931 has also been shown to have potential as a biomarker for various diseases, including cancer. The authors have shown that LINC01931 can be expressed in a variety of cancer types and that its expression is associated with the development and progression of these diseases. The authors have also shown that LINC01931 can be used as a biomarker for disease diagnosis, as it can be detected in the bloodstream at concentrations that are detectable by qRT-PCR.

Conclusion

LINC01931 is a long non-coding RNA that has been shown to play a variety of roles in cellular processes. Its function as a drug target or biomarker continues to be under investigation, and its potential as a drug target for cancer therapy is currently being explored. Further research is needed to fully understand the functions of LINC01931 and its potential as a drug

Protein Name: Long Intergenic Non-protein Coding RNA 1931

The "LINC01931 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01931 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets